APA (7th ed.) Citation

E, E., DG, R., IC, S., S, C., DTY, C., CE, C. H., . . . ES, C. (2023). Tozorakimab (MEDI3506): An anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Scientific reports, 13(1), 9825. https://doi.org/10.1038/s41598-023-36642-y

Chicago Style (17th ed.) Citation

E, England, et al. "Tozorakimab (MEDI3506): An Anti-IL-33 Antibody That Inhibits IL-33 Signalling via ST2 and RAGE/EGFR to Reduce Inflammation and Epithelial Dysfunction." Scientific Reports 13, no. 1 (2023): 9825. https://doi.org/10.1038/s41598-023-36642-y.

MLA (9th ed.) Citation

E, England, et al. "Tozorakimab (MEDI3506): An Anti-IL-33 Antibody That Inhibits IL-33 Signalling via ST2 and RAGE/EGFR to Reduce Inflammation and Epithelial Dysfunction." Scientific Reports, vol. 13, no. 1, 2023, p. 9825, https://doi.org/10.1038/s41598-023-36642-y.